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Aim To explore the association between plasma fatty ac-
ids composition and the severity of clinical symptoms in 
Croatian war veterans with posttraumatic stress disorder 
(PTSD).
Methods This cross-sectional study included 62 men di-
agnosed with PTSD caused by combat activities during 
the War in Croatia 1991-1995. Clinician-Administered PTSD 
Scale (CAPS), Hamilton Anxiety Rating Scale (HAM-A), and 
Hamilton Depression Rating Scale (HAM-D-17) were used. 
Plasma fatty acids composition was determined by gas 
chromatography. Data about life-style habits were collect-
ed by a structured interview. To evaluate the association 
between plasma fatty acid levels and PTSD severity scales, 
multivariate general linear models (GLM) were applied 
while controlling for different confounders.
Results Significant negative correlations were found be-
tween plasma eicosapentaenoic acid (EPA, 20:5n-3) level 
and the scores on psychological scales (τ = -0.326, P < 0.001 
for CAPS; τ-0.304,  P = 0.001 for HAM-A; and τ = -0.345, 
P < 0.001 for HAM-D-17). GLM confirmed that PTSD severity 
was affected by EPA (Wilks’Λ = 0.763-0.805, P = 0.006-0.018, 
ηp 0.195-0.237), arachidonic acid (AA)/EPA (Wilks’Λ = 0.699-
0.757,  P = 0.004, ηp 0.243-0.301), and dairy products con-
sumption (Wilks’Λ = 0.760-0.791,  P = 0.045-0.088, ηp 0.128-
0.111). No other fatty acid or dietary/lifestyle variable was 
significant ( P = 0.362-0.633).
Conclusion The study suggests that lower EPA levels are 
associated with the severity of clinical symptoms in PTSD.
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Over the last decade, scientific community has developed 
a rapidly growing interest in the associations between me-
tabolism of n-3 polyunsaturated fatty acids (PUFA) and a 
wide range of psychiatric disorders (1). Fish and marine de-
rivatives, such as fish oil, are the primary sources of docosa-
hexaenoic acid (DHA; C22:6n-3) and eicosapentaenoic acid 
(EPA; C20:5n-3), the two key n-3 PUFA present in brain lipids, 
particularly phospholipids. n-3 PUFA exhibit various physi-
ological properties: neuroinflammatory, vascular, and gene 
control properties. They also play a significant role in the 
composition and fluidity of neuron membranes and conse-
quently have regulatory effects on various neurotransmit-
ter systems or signal transduction (2,3). Both EPA and DHA 
maintain properties of the lipid bilayer within cellular mem-
branes (4). They concentrate at synapses in the human 
brain and are essential for neuronal functioning (5). Experi-
ments with animals on fat-free diet showed that metabolic 
mechanisms tended to compensate for the lack of essential 
fatty acids by increased synthesis of endogenous unsatu-
rated fatty acids (6). However, since n-6 and n-3 unsaturat-
ed fatty acids compete for the same metabolic pathways, 
the balance between n-6 and n-3 PUFA is important for the 
overall optimal functioning of the organism (7). n-6 and n-3 
PUFA cannot be synthesized by the human body and must 
be supplied by nutritional sources. Therefore, the ratios of 
n-6/n-3 PUFA, arachidonic acid (C 20:4n-6) to EPA (AA/EPA) 
and AA/DHA can be used for nutritional assessment. Fur-
thermore, AA and EPA are used as initial substrates in the 
synthesis of eicosanoids with pro- (ie, AA) or anti-inflamma-
tory (ie, EPA) effects, and the AA/EPA ratio indicates which 
one might dominate. EPA and DHA are the main n-3 PUFA 
in the brain, but it is still not clear whether one of them (and 
which one) is more important, or if their ratio is a prerequi-
site for proper functioning of the brain.
Significant negative correlation has been demonstrated 
between annual fish consumption and the prevalence of 
major depression, as well as between the severity of de-
pressive symptoms and plasma levels of n-3 PUFA (8,9). 
Higher n-6/n-3 ratio has been observed in depressed pa-
tients than in non-depressed controls, thus demonstrating 
the implication of n-6 PUFA in depression (8-10).
Psychological stress was found to be associated with al-
tered proportions of n-6 unsaturated plasma fatty acids 
(11) and n-6/n-3 PUFA ratio was related to alterations in 
serotonergic, as well as in catecholaminergic neurotrans-
mission system (5), whereas the n-3 PUFA deficit was re-
lated to the alteration in serotonergic and dopaminer-
gic systems (12).
These neurotransmitter systems are involved in the neu-
robiological model of posttraumatic stress disorder (PTSD) 
(13). PTSD is an anxiety disorder caused by exposure to a 
traumatic event that involved a threat to the physical in-
tegrity of self or others (14).
PTSD symptoms are significantly alleviated in patients who 
took n-3 fatty acids after the injury causative to their PTSD 
(15). Also, recent case-control and n-3 PUFA supplementa-
tion clinical trials suggest that an increased intake of n-3 
PUFA, whether through whole foods or supplements, may 
be beneficial in conditions of acute stress and some types 
of anxiety disorders, which points to possible abnormali-
ties of fatty acids composition in anxiety disorders (7,16). 
The aim of our study was to test the associations between 
fatty acid levels and the severity of PTSD symptomatology. 
We hypothesized that low levels of EPA and DHA, or to-
tal n-3 PUFA, were associated with an increased severity of 
PTSD symptoms.
PArtIcIPANts AND MethoDs
Participants
This cross-sectional study included patients from the 
pool of veterans involved in our outpatient PTSD pro-
gram at the Department for General Psychiatry, Univer-
sity Psychiatric Hospital Vrapče, Zagreb, Croatia. The study 
was approved by the Ethics Committee of the University 
Psychiatric Hospital Vrapče, Zagreb, Croatia. Participants 
were consecutively recruited from June 2010 till February 
2011, and all 62 included participants were male outpa-
tient veterans. Patients were eligible if they met the fol-
lowing inclusion criteria: (i) met the DSM-IV-TR (14) and 
the International Classification of Disorder (ICD-10) (17) 
diagnostic criteria for PTSD, which was reestablished 
by experienced certified psychiatrists during the inclu-
sion screening procedures; (ii) participated in the War in 
Croatia 1991-1995, (iii) had the Clinician-Administered 
PTSD Scale (CAPS) (18) score equal to or greater than 50 
(19), and (iv) had been on a stable dose of sertraline (50 
mg/d) for at least three months continuously prior to the 
study beginning. The exclusion criteria were as follows: 
(i) used n-3 PUFA supplements any time in the past, (ii) 
used any medication (other than sertraline) two weeks 
prior to the study beginning, (iii) had concurrent psychi-
atric or somatic disease, and (iv) suffered from alcohol or 
drug abuse. Participation in the study was voluntary and 
prior to any study procedure all participants signed an 
informed consent.
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Antidepressants
The two antidepressant drugs, sertraline and paroxetine, 
have Food and Drug Administration’s approval for the treat-
ment of PTSD (20,21). It seems that antidepressants have 
no relevant effect on composition of fatty acids (22,23), but 
paroxetine can cause weight gain and, therefore, influence 
the body mass index (BMI) (21). As BMI appeared as a co-
founder in some studies about the fatty acid profile and 
psychiatric symptomatology (23,24), we included only vet-
erans who used sertraline alone.
Questionnaires
In this study four questionnaires were used: Clinician-Ad-
ministered PTSD Scale (CAPS), Hamilton Anxiety Rating 
Scale (HAM-A) (25), Hamilton Depression Rating Scale-
17 (HAM-D-17) (26), and a socio-demographic question-
naire (27). Experienced psychiatrists who administered the 
scales were trained and certified for the implementation 
of each specific scale in its original English version. Con-
sidering that the scales were clinician-administered, they 
were used in their original formats and language, while the 
interview itself was conducted in Croatian. To avoid possi-
ble participants’ exaggeration of symptoms with an aim to 
obtain compensation, we used only clinician-administered 
scales (28,29). PTSD symptomatology was assessed by psy-
chiatrists licensed for CAPS administration (18). Since anx-
ious and depressive symptoms are part of the PTSD clinical 
presentation, HAM-A and the HAM-D-17 were also applied 
by examiners licensed for HAM-A and HAMD-17 scales.
The CAPS is a structured interview that categorically diag-
noses and measures the severity of PTSD symptoms as de-
fined by the DSM-IV-TR. To meet the criterion of PTSD, a 
particular symptom has to have the sum of the frequency 
(score 0 = “none of the time” to 4 = “most of the time”) and 
intensity scores (scale 0 = “none” to 4 = “extreme”) (19). In-
ter-rater reliability for CAPS is high, ranging from 0.92 to 
1.00 for “frequency” ratings, and 0.93 to 0.98 for “intensity” 
ratings; the global severity correlation is 0.89 (30). Test-
retest reliability ranges from 0.90 to 0.98 for 17-item core 
symptom scale (18). Strong convergent validity has been 
demonstrated against the Structured Clinical Interview for 
DSM-IV (SCID) PTSD module (0.83) (31).
HAM-A and HAM-D-17 are the most widely used clinician-
administered anxiety and depression assessment scales. 
The used HAM-A has 14 items and the severity of anxiety is 
graded as follows: normal (0-13 points), mild (14-17 points), 
moderate (18-24 points), and severe (≥25 points). The used 
HAM-D-17 has 17 items and the severity of depression is 
graded as follows: normal (0-6 points), mild (7-16 points), 
moderate (17-24 points), and severe (≥25 points). Scores 
of ≥17 on HAM-A and HAM-D-17 scales are usually used as 
a marker of clinically relevant levels of anxious/depressive 
symptoms (25,26). Although HAM-D-17 is not validated in 
Croatia, it is translated to Croatian by one of the authors 
(NM) (32). All examiners in our study are licensed and high-
ly experienced in applying the English versions of all scales, 
and this mode of evaluation is in concurrence with psychi-
atric scientific practice in our country.
For general demographic data, as well as nutritional and 
life-style habits, we used a validated structured interview 
(27). During the interview, an experienced nutritionist/bio-
chemist explained the criteria for a good quality diet to all 
participants according to recommendations (27). Variables 
specific for the study (sleep duration, loss of a close person) 
were included in the questionnaire.
Blood sample collection
Vein blood samples were taken from the left forearm be-
tween 8 and 9 am after an overnight fast, and collected into 
5 mL vacutainer tubes (Becton Dickinson, Franklin Lakes, 
NJ, USA). They were centrifuged at 3000 rpm for 10 min-
utes at 15°C; the serum was separated and stored at -20°C 
until further analysis.
Fatty acids analysis
The fatty acids analysis was undertaken in one batch af-
ter all blood samples had been collected. Total lipids were 
extracted from serum with a mixture of isopropanol/chlo-
rophorm (1.5:1 v/v) (33). Trans-esterification of fatty acids 
to methyl esters was performed according to International 
Standard ISO 5509:2000(E) (34), and the composition of fat-
ty acid methyl esters was analyzed by a validated method 
ISO 5508:1990(E) (35). Gas chromatography was performed 
on SRI 8610C Gas chromatograph (SRI Instruments Chro-
matography Systems, Torrance, CA, USA), equipped with a 
flame ionization detector and a capillary column 007-CW 
(Quadrex Corporation, Woodbridge, CT, USA), length 60 m, 
i.d. 0.25 mm, and film thickness 0.25 µm. Hydrogen was 
used as a carrier gas at a flow of 60 mL/min in a split mode. 
The initial oven temperature of 150°C was maintained 
for 3 minutes then increased to 220°C at a rate of 8°C/
min, and the final temperature was kept constant for 
30 minutes. The injector and detector temperatures 
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were 250°C and 260°C, respectively. Fatty acid methyl es-
ters were identified by comparison of their retention times 
to those of known reference standards (Supelco Inc, Belle-
fonte, PA, USA). Reproducibility and equimolar response 
experiments were performed with methyl heptadecanoat 
as internal and/or external standard, and the full procedure 
was applied to duplicate samples. Data were collected and 
analyzed using Peak Simple 3D, Version 2.97 (SRI Inc, Tor-
rance, CA, USA). The results are reported as weight percent 
(wt %) of total fatty acids, and certain ratios of interest were 
calculated.
statistical analysis
Data were analyzed with statistical package SPSS 19.0 (IBM 
Corp, Armonk, NY, USA), apart from structural equation 
modeling, which was undertaken using the SPSS Amos 
22.0 (IBM Corp). Depending on the data distribution, quan-
titative data were described by mean and standard devia-
tion (SD) or median and interquartile range. For categorical 
data, absolute numbers and percentages were used. Pear-
son correlation coefficient was used to estimate correla-
tions between psychological scales and between fatty ac-
ids and psychological scales after eliminating the outliers 
and ln-transforming the variables whose distribution sig-
nificantly deviated from the normal. Outliers (noutliers from 0 
to 2) were defined as extreme scores (mean ±3SD), which 
distorted the size of the correlation coefficient. In parallel 
with Pearson, Kendall tau correlation was used as sensitiv-
ity analysis of data manipulation. Demographic/lifestyle 
variables possibly causing spurious correlations of PUFA 
with PTSD severity were identified by literature search (ie, 
age, BMI), or by Kendall correlation analysis (ie, preferred 
oil, fish, dairy product consumption, and sleeping). Addi-
tionally, smoking status, physical activity, and overall diet 
quality were also included in the set of possible confound-
ers. Independent associations of fatty acids with scores on 
PTSD severity scales that were confirmed as significant dur-
ing partial correlation analysis were further investigated in 
a series of multivariate general linear models (GLM) using 
scores on CAPS, HAM-A, or HAM-D-17 scales as dependent 
variables. In all cases, the assumptions for applying multi-
variate GLM were checked by testing the normality of de-
pendent variables distribution (assumption of multivariate 
normality) and Box’M statistics (assumption of homogene-
ity of variance-covariances matrices).
Since we could include up to three independent vari-
ables in a multivariate model (due to a sample size lim-
itations), modeling was performed in several steps. 
First, independent association between a fatty acid (EPA, 
AA/EPA, EPA/DHA) level and PTSD severity was evaluated 
using two additional covariates: a) a variable for which it 
was reasonable to assume that it influenced the profile of 
fatty acids: preferred oil, fish, and dairy products consump-
tion or sleep duration; and b) n-6 PUFA levels that compete 
for the same metabolic pathways with n-3 PUFA (in models 
with EPA and EPA/DHA). The main effect of n-6 PUFA was 
also included as a covariate in the model with AA/EPA, since 
EPA level was the primary determinant of the magnitude 
of AA/EPA in our sample, due to a marked n-3 PUFA defi-
ciency (36). Covariates that demonstrated significant mul-
tivariate effects: EPA, AA/EPA, EPA/DHA, and dairy products 
consumption; as well as BMI and age, which were selected 
based on previous studies (37), were introduced in the sec-
ond analysis step in which fatty acid levels, dairy products 
consumption, and BMI were chosen as independent vari-
ables with the strongest multivariate effects. Finally, three 
multivariate models of PTSD severity were formed, using 
BMI, dairy products consumption, and either EPA, AA/EPA, 
or EPA/DHA as covariates. The Bootstrap method was used 
to estimate the robustness of regression coefficients.
In addition to multivariate analysis, we used structural equa-
tion modeling (SEM) (38). In this model, we defined PTSD 
as the underlying phenomenon measured by three psycho-
logical scales and introduced it in the model as the latent 
(unobserved) variable. AA/EPA ratio was the strongest pre-
dictor in multivariate analysis, with EPA being the strongest 
determinant of the ratio in n-3 PUFA deficiency conditions. 
Therefore, either AA/EPA or both: AA and EPA were intro-
duced as exogenous variable(s) in the model, together with 
the dairy products consumption, which was included based 
on multivariate analysis results and indications from litera-
ture (39,40). We modeled both the direct (exogenous vari-
able) and the indirect (covariate of fatty acids) influence of 
dairy products consumption on PTSD in the model. For mul-
tiple testing we used Bonferroni’s correction, which incorpo-
rates correlation structures between multiple contrasts and 
multiple variables (41,42). Unless otherwise stated, P values 
<0.05 were considered significant.
resuLts
Demographic and lifestyle characteristics
The majority of participants had a secondary school edu-
cation level, sedentary lifestyle, and slept less than 5 hours/
night. In food preparation they most commonly used sun-
flower oil, consumed dairy products a few times a week, 
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and presumed to have generally good or moderate overall 
diet quality (Table 1).
Psychometric characteristics
The patient who entered the study with the least score 
had 52 points on CAPS. On HAM-A scale, 20 participants 
had over 17 points, indicating clinically relevant level of 
anxiety, although according to DSM-IV-TR they did not 
meet the diagnostic criteria for any other anxious dis-
order except PTSD. Similarly, 10 participants had clini-
cally relevant level of depressive symptoms but did not 
meet the DSM-IV-TR criteria for current major depressive 
disorder. Based on the severity of clinical presentation, 
these patients could be classified as moderately anx-
ious or moderately depressed. Comparable significant 
correlations were identified between CAPS and HAM-A 
scores (r = 0.901, 95% confidence interval [CI] 0.865-0.935; 
P < 0.001), and CAPS and HAM-D-17 scores (r = 0.868, 95% 
CI 0.736-0.943; P < 0.001).
Fatty acid composition
The composition of fatty acids in serum lipids was ex-
pressed as the ratio of a certain fatty acid in total fatty ac-
ids pool (Table 2). Fatty acids were composed mainly of 
PUFA (almost 39%), among which linoleic acid prevails (LA, 
C18:2n-6). Consequently, a high n-6/n-3 ratio was calculat-
ed. Actually both, LA and AA, contributed to this ratio as re-
vealed by high AA/EPA and AA/DHA ratios. Saturated fatty 
acids made up approximately 36% and monounsaturated 
fatty acids the rest.
tABLe 1. Demographic and clinical characteristics of partici-
pants (n = 62)*
characteristic
Age (years), mean (SD) 47.1 ± 5.9
Body mass index (kg/m2), mean (SD) 28.9 ± 4.5
Psychological scale scores, mean (sD)
CAPS 69.2 ± 9.8
HAM-A 16.5 ± 2.2
HAM-D-17 13.3 ± 4.0
Level of education†, n (%)
elementary school (≤8 y)  7 (11.3)
secondary school (>8≤12 y) 42 (67.7)
high school (>12 y)  6 (9.7)
smoking status†, n (%)
never 16 (25.8)
former 18 (29.0)
current 21 (33.9)
consumption of fish and seafood†, n (%)
<1/week 40 (51.6)
1/week 12 (19.4)
>1/week  3 (4.8)
consumption of dairy products†, n (%)
<1/week  9 (14.5)
a few times a week 39 (62.9)
>1/d  7 (11.3)
Physical activity†, n (%)
sedentary (≤1/mo) 26 (42)
intermediate (2-3/week) 23 (37.1)
sufficient (≥3/week)  6 (9.7)
oil type†, n (%)
sunflower 40 (64.5)
olive  6 (9.7)
other  9 (14.5)
overall diet quality†, n (%)
very good  3 (4.8)
good 28 (45.2)
moderate 22 (35.5)
low  2 (3.2)
sleep duration†, n (%)
<5 h/night 29 (46.7)
6-8 h/night 25 (40.3)
>8 h/night  1 (1.6)
Loss of a close person†, n (%)
no 19 (30.6)
yes 36 (58.1)
*Abbreviations: cAPs – clinician-Administered PtsD scale; hAM-A 
– hamilton Anxiety rating scale; hAM-D-17 – hamilton Depression 
rating scale-17.
†the sum does not add up to total because of 7 missing values.
tABLe 2. Fatty acid composition (wt %) of serum lipids in 
patients with posttraumatic stress disorder. All values are 
expressed as median and interquartile range
Fatty acids Percentage
SFA 36.4 (34.4-39.0)
MUFA 22.6 (20.6-26.5)
PUFA 39.4 (35.0-44.1)
Total n-6 PUFA 38.8 (34.1-43.1)
Total n-3 PUFA  1.4 (0.7-2.3)
AA  8.8 (7.3 -11.4)
EPA  0.1 (0.1-0.4)
DHA  0.5 (0.2-1.0)
n-6/n-3 PUFA 30.0 (15.8-52.3)
AA/EPA 53.9 (29.3-129.7)
AA/DHA 17.6 (7.7-38.9)
EPA/DHA  0.5 (0.1-0.9)
*Abbreviations: PtsD – posttraumatic stress disorder; sFA – saturated 
fatty acids; MuFA – monounsaturated fatty acids; PuFA – polyunsatu-
rated fatty acids; AA – arachidonic acid (c20:4n-6); ePA – eicosapen-
taenoic acid (c20:5n-3); DhA – docosahexaenoic acid (c22:6n-3).
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Associations between serum fatty acid levels and 
psychometric characteristics
Significant negative correlations were found between 
plasma EPA levels and scores on CAPS, HAM-A, and HAM-
D-17 scales (τ = -0.326,  P < 0.001; τ = -0.304,  P = 0.001; 
τ = -0.345,  P < 0.001, respectively; corrected significance 
level α = 0.016) (Table 3). Also, there were significant 
negative correlations between plasma EPA/DHA ratio 
and scores on HAM-A and HAM-D-17 scales (τ = -0.224, 
P = 0.015; τ = -0.179,  P = 0.047), whereas correlation be-
tween plasma EPA/DHA ratio and CAPS score was border-
line. Contrary to EPA and EPA/DHA, AA/EPA ratio was sig-
nificantly positively correlated with psychological scales 
scores (τ = 0.345,  P < 0.001; τ = 0.348,  P = 0.001; τ = 0.346, 
P < 0.001, respectively).
Levels of other analyzed fatty acids, or their ratios, were not 
significantly correlated with posttraumatic, anxiety, or de-
pressive symptomatology scores ( P ranging from 0.208 to 
0.917). Likewise, in order to assess the possibility that some 
of these “correlations” were distorted by the effect of the 
confounding variable, we performed partial correlation 
analysis between PTSD severity (measured as scores on 
CAPS, HAM-A, and HAM-D-17 scales) and fatty acids level. 
None of the partial correlations was in contradiction with 
zero correlation finding. In particular, none of the non-sig-
nificant fatty acid correlations was found to be significant 
tABLe 3. correlations between fatty acid levels and posttraumatic stress disorder symptoms, n = 62
cAPs hAM-A hAM-D-17
Measure τ P† τ P τ P
SFA -0.155 0.080 -0.201 0.028 -0.066 0.464
MUFA 0.082 0.355 0.069 0.450 0.059 0.510
PUFA 0.053 0.551 0.109 0.236 0.036 0.689
n-6 PUFA 0.058 0.511 0.116 0.208 0.039 0.660
n-3 PUFA -0.075 0.394 -0.025 0.782 -0.071 0.428
AA 0.037 0.679 0.085 0.354 0.002 0.981
EPA -0.326 <0.001 -0.304 0.001 -0.345 <0.001
DHA -0.069 0.436 -0.010 0.917 -0.067 0.457
n-6/n-3 PUFA 0.084 0.343 0.069 0.450 0.075 0.407
AA/EPA 0.345 <0.001 0.348 <0.001 0.346 <0.001
AA/DHA 0.085 0.336 0.054 0.559 0.070 0.435
EPA/DHA -0.169 0.056 -0.224 0.015 -0.179 0.047
*Abbreviations: PtsD – posttraumatic stress disorder; sFA – saturated fatty acids; MuFA – monounsaturated fatty acids; PuFA – polyunsaturated 
fatty acids; AA – arachidonic acid (c20:4n-6); ePA – eicosapentaenoic acid (c20:5n-3); DhA – docosahexaenoic acid (c22:6n-3); cAPs – clinician-
Administered PtsD scale; hAM-A – hamilton Anxiety rating scale; hAM-D-17 – hamilton Depression rating scale-17.
†corrected significance level α = 0.016; τ - Kendall’s tau correlation coefficient.
tABLe 4. Multivariate general linear models of a severity of PtsD symptoms (measured by scores on cAPs, hAM-A, and hAM-D-17 
scales) with covariates: fatty acid level and BMI; and a fixed factor: dairy products consumption, n = 62
Predictors strength
covariates Wilks’ lambda P-value† Partial eta squared
EPA 0.706 0.002 0.294
Dairy products consumption 0.756 0.061 0.131
BMI 0.857 0.087 0.143
AA/EPA 0.629 <0.001 0.371
Dairy products consumption 0.726 0.033 0.148
BMI 0.876 0.131 0.124
EPA/DHA 0.833 0.051 0.167
Dairy products consumption 0.727 0.033 0.142
BMI 0.844 0.065 0.156
*Abbreviations: PtsD – posttraumatic stress disorder; BMI – body mass index (kg/m2); AA – arachidonic acid (c20:4n-6); ePA – eicosapentaenoic acid 
(c20:5n-3); DhA – docosahexaenoic acid (c22:6n-3); cAPs – clinician-Administered PtsD scale; hAM-A – hamilton Anxiety rating scale; hAM-D-17 – 
hamilton Depression rating scale-17.
†significance level 0.05.
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even after we included age, BMI, smoking status, physical 
activity, sleeping duration, overall diet quality, and type of 
oil, fish, or dairy products consumption as a confounder. At 
the same time, all significant correlations of fatty acids re-
mained significant (Table 3).
Independent correlations between EPA, AA/EPA, EPA/DHA, 
and PTSD severity were further assessed through several 
steps by multivariate GLMs, with scores on CAPS, HAM-A, 
and HAM-D-17 scales entered as dependent variables.
Models that included covariates: fatty acids (EPA, AA/EPA 
or EPA/DHA, and n-6 PUFA levels which compete with n-3 
PUFA levels) and a fixed factor (a potential confounder re-
lated to dietary/lifestyle quality such as oil preference, con-
sumption of dairy products, fish consumption, or sleep du-
ration) confirmed that PTSD severity was affected by EPA 
(Wilks’Λ = 0.763-0.805, P = 0.006 to 0.018, ηp 0.195-0.237), 
AA/EPA (Wilks’Λ = 0.699-0.757, P = 0.004, ηp 0.243-0.301), 
and dairy products consumption (Wilks’Λ = 0.760-0.791, 
P = 0.045-0.088, ηp 0.128-0.111). On the contrary, no other di-
etary/lifestyle variable was significant (P = 0.362-0.633). EPA/
DHA ratio also did not demonstrate significant multivariate 
effect (Wilks’Λ = 0.901-0.960, P = 0.185-0.596, ηp 0.040-0.099) 
but was nevertheless introduced to further analysis.
The next stage of analysis consisted of running three sepa-
rate multivariate GLMs. The strongest effect was observed 
for AA/EPA, followed by EPA and EPA/DHA. The multivari-
ate effect of dairy products consumption was also signifi-
cant, whereas the effect of BMI exhibited borderline sig-
nificance (Table 4).
Finally, a structural equation model (SEM) was built in 
order to construct a causal model of the relationships 
among variables. The model was built on complete data 
of 62 participants and had the best fit (Figure 1). The de-
parture of the data from the model was not significant 
(χ28 = 6751, P = 0.564), thereby indicating a good model fit, 
as confirmed by Root Mean Square Error of Approxima-
tion (RMSEA) fit index <0.001 (90% CI from 0 to 0.138). All 
of the paths made significant contributions to the success 
of the model, P < 0.05 (unlike covariances between dairy 
products consumption and PUFA). The percentage of vari-
ance explained by PTSD indicated that CAPS was the most 
precise measurement scale (97%), followed by HAM-A 
(86%) and HAM-D-17 (78%). Exogenous variables AA, EPA, 
and dairy products consumption in total explained 34% 
of PTSD variance. Correlation coefficients indicated plausi-
ble biological interactions. EPA moderately and negatively 
correlated with PTSD severity, whereas AA and dairy prod-
ucts consumption were weakly and positively correlated. 
DHA, on the other hand, was not identified as a significant 
covariant.
DIscussIoN
Fatty acids and the severity of PtsD symptoms
Our study revealed an inverse correlation between EPA, 
AA/EPA, and EPA/DHA levels and the severity of the PTSD 
symptoms. No significant correlations were found be-
tween AA and DHA levels, or any other analyzed fatty 
acid, and the score on the psychiatric scales. Therefore, 
the AA/EPA and EPA/DHA ratios could have corre-
FIGure 1. Best-fitting structural equation model of post-trau-
matic stress disorder (PtsD) severity showing relationships be-
tween unobserved endogenous (PtsD) and observed endog-
enous (clinician-Administered PtsD scale, hamilton Anxiety 
rating scale, and hamilton Depression rating scale-17) and 
exogenous (dairy products consumption, eicosapentaenoic 
acid, and arachidonic acid levels) variables. the figure also 
shows unobserved exogenous error (e1-e4) variables, percent-
age of variance explained by dependent variables (rectangles 
and ellipse), and correlation between variables (arrows).
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lated with PTSD symptoms solely due to EPA level, which 
seems to be the only fatty acid that had a significant cor-
relation with PTSD symptoms. Our results are consistent 
with the report that plasma EPA level was inversely associ-
ated with the severity of depressive symptoms in elderly 
subjects receiving antidepressant treatment (23). Similar-
ly, another study reported a negative correlation between 
EPA level and severity of depression (43). The Health 2000 
Survey, which included 2608 male participants, has also 
shown a significant relationship between serum EPA lev-
els and psychological distress (44).
Data on the correlation between DHA and psychiatric dis-
order are inconsistent. Both a significant negative correla-
tion between DHA concentrations and the severity of so-
cial anxiety disorder (45) as well as a positive association 
between serum DHA level and distress scores (24) were 
reported.
Our results can be ascribed to low n-3 PUFA intake and/or 
to an altered fatty acids metabolism in patients with PTSD. 
Stress alters gastrointestinal motility, and in this way pos-
sibly influences fatty acids’ absorption (46). On the other 
hand, neurotransmitter dysfunction related to a disorder 
process could alter the metabolism of n-3 PUFA by influenc-
ing the activities of the rate-limiting enzymes (45). The op-
posite mechanism is also possible. Both n-6 and n-3 PUFA 
compete for the same set of enzymes involved in desatu-
ration and elongation. If n-6 PUFA level outmatches fatty 
acids from n-3 series, the resulting misbalance in neuronal 
membranes will result in an impaired signal transduction.
effect of dairy products consumption and BMI on the 
severity of PtsD symptoms
We found both a significant multivariate effect of dairy 
products consumption and a borderline significant multi-
variate effect of BMI on the severity of PTSD symptoms. Al-
though the evidence is scarce, two studies have associated 
dairy products consumption with increased anxiety, stress, 
depression scores, and risk of cognitive decline (39,40). An 
extensive variety of biological, cognitive, behavioral, and 
social factors may underlie the relationship between BMI 
and depression symptoms (47,48). It was presumed that 
depression can lead to obesity via physiological and psy-
chosocial pathways, including elevated stress reaction, im-
munological dysfunction, and hypothalamic-pituitary-ad-
renal (HPA) axis (47). In addition, dysfunctions in HPA axis 
and the immune system were also established in PTSD 
patients (49,50).
PtsD treatment and n-3 PuFA supplementation
Pharmaceutical treatment of PTSD dominant core symp-
toms and the related anxiety and depressive symptoms 
has been shown as successful (51-54). However, combat-
related PTSD causes a stronger functional impairment and 
is less responsive to treatment than PTSD related to other 
traumas (28,29,53,54). It is worth mentioning that animal 
studies have confirmed that n-3 unsaturated fatty acids 
enhance hippocampal neurogenesis (55). In PTSD, the hip-
pocampal volume is reduced and a long-term over-activi-
ty of HPA axis causes adjacent adaptive changes of gluco-
corticoid receptors with subsequently deleterious effects 
for the hippocampal neurons (56,57). Assuming that the 
animal model could be representative for humans, PTSD 
patients may benefit from n-3 PUFA supplementation, as 
it could enhance the hippocampal neurogenesis. Previous 
studies showed a significant increase in serum lipids con-
centration and associated risk factors for atherosclerosis 
and coronary artery disease in a sample of veterans suf-
fering from chronic PTSD (58,59). Associations of n-3 PUFA 
deficit with many psychiatric disorders (1), as well as favor-
able effects of n-3 PUFA on the cardiovascular system, are 
well established (60). This makes n-3 PUFA supplementa-
tion a new potential treatment approach for psychiatric 
disorders, with added beneficial effect on the comorbid 
cardiovascular disorders.
As shown in a recent review, a number of clinical trials in-
vestigated the effects of n-3 PUFA supplementation in 
depressive disorder, schizophrenia, bipolar disorder, and 
social anxiety disorder (1). However, to date no study has 
investigated the supplementary effects of n-3 PUFA status 
in chronic, combat-related PTSD.
Limitations and strengths
Although our sample size is relatively small, the highly sig-
nificant results observed by a series of different statistical 
approaches obviously indicate certain effects of fatty ac-
ids composition on the severity of PTSD symptoms. Fur-
ther studies should gather more detailed dietary data as 
it is well known that dietary choices affect plasma fatty 
acid composition. Also, it would be of interest to make a 
comparison with a control group unaffected by PTSD. The 
cross-sectional design of our study did not allow us to de-
termine whether the lower plasma EPA levels contributed 
to PTSD development or vice versa. It could also be con-
sidered a limitation that patients’ last meal before blood 
collection was not of the same quantity and components 
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and it was not taken at the same time, but the patients 
were allowed to follow their own nutritional habits. There 
is no doubt that nutrition affects blood fatty acids compo-
sition both in short- and long-term. However, blood sam-
ples were taken at least 12 hours after the last meal, which 
means that fatty acids taken from the gut and released 
into the bloodstream via chylomicrons had allready been 
cleared out and could not have significantly affected the 
average fatty acid composition.
However, our study has several strong points. We studied 
a homogenous group of participants with clinically estab-
lished PTSD who had been exposed to the same type of 
trauma experience. We recruited only male patients in or-
der to exclude the influence of gender and the associated 
hormones on the metabolism of lipids and fatty acids. As 
the activity of enzymes responsible for the synthesis of EPA 
and DHA decreases with age, the long-chain PUFA status, 
notably DHA, becomes more dependent on dietary sup-
ply (23,61). Having this in mind we recruited participants 
younger than 65 years, thus contributing to the better ho-
mogeneity of the study sample.
In conclusion, our study showed a significant negative as-
sociation between EPA levels and chronic, combat-related 
PTSD symptoms, thus confirming our hypothesis. Further 
longitudinal studies on a larger sample are necessary to af-
firm our results and to reveal the mechanisms underlying 
the relationship between plasma PUFA levels and PTSD. 
We suggest further investigations of n-3 PUFA supplemen-
tation in combat-related PTSD veterans since data indicate 
potential multiple benefits of this approach in reduction of 
negative consequences of the illness.
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